Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,600 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Skin Patch Clear all

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 25 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy
Interventions: Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell), Temperature Probe; Device · Other
Lead sponsor: Chattem, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Skin Lesion
Interventions: Photos; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nicotine Dependence
Interventions: Cognitive Behavioural Therapy, Contingency Management, Nicotine Transdermal Patch; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 14 Years to 19 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Smoking Cessation
Interventions: Ganaxolone, Nicotine Patch; Drug
Lead sponsor: Jed E. Rose; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more

Conditions: Needle Phobia, Phobic Disorders
Interventions: Enhanced Needle Phobia Intervention, Standard Needle Phobia Intervention; Other
Lead sponsor: Davita Clinical Research; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Rancho Cordova, California • Sacramento, California • Asheville, North Carolina

Conditions: Psoriasis
Interventions: Luma Light System; Device
Lead sponsor: Illumicure Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Santa Rosa, California • Knoxville, Tennessee • San Antonio, Texas + 1 more

Conditions: Cocaine-Related Disorders
Interventions: Selegiline; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 16
States / cities: Tucson, Arizona • Berkeley, California • Los Angeles, California + 11 more

Conditions: Major Depression
Interventions: Selegiline Transdermal System; Drug
Lead sponsor: Somerset Pharmaceuticals; Industry
Eligibility: 65 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 15
States / cities: Chula Vista, California • San Diego, California • Upland, California + 11 more

Conditions: Tobacco Dependence
Interventions: Nicotine Patch, Nicotine Gum; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 13 Years to 17 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sarcoidosis
Interventions: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures, Skin biopsy; Drug · Procedure
Lead sponsor: Kevin F. Gibson; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Epilepsy
Interventions: ProGuardian; Device
Lead sponsor: Cyberonics, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Chicago, Illinois • Charlotte, North Carolina • Austin, Texas + 2 more

Conditions: Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection; Drug · Procedure · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension
Interventions: Anti-hypertensive agent: amlodipine, Anti-hypertensive agent: Chlorthalidone, Anti-hypertensive agent: Losartan, Home BP monitoring with cuffed device, Home BP monitoring with cuffed device + BP patch, Home BP monitoring with cuffed device + BP watch; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Tobacco Use Disorder
Interventions: Nicotine Patch, Sustained Release Bupropion; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 45 Years
Enrollment: 594 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Skin Sensitisation
Interventions: Blue Non Sterile Powder Free Nitrile Examination Gloves; Device
Lead sponsor: Central Medicare Sdn. Bhd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Fairfield, New Jersey

Conditions: Atrial Fibrillation
Interventions: Single lead ambulatory ECG patch; Diagnostic Test
Lead sponsor: Fitbit LLC; Industry
Eligibility: 22 Years and older
Enrollment: 450,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Pain, Cancer
Interventions: Fentanyl Transdermal Matrix Patch ZR-02-01; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Loma Linda, California • Winston-Salem, North Carolina

Conditions: Hernia
Interventions: PARIETEX™ Composite Ventral Patch; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Tampa, Florida • Baton Rouge, Louisiana • Jefferson City, Missouri + 2 more

Conditions: Device Latency
Interventions: Placebo, Combination product of Aripiprazole + IEM + Sensor + MIND1 Application; Drug · Combination Product
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions: Capsaicin Dermal Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 35
States / cities: Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more

Conditions: Type 1 Diabetes
Interventions: Insupatch, Continuous glucose sensor; Device
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 44 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Dermatitis, Eczematous
Interventions: Metal Allergen Epicutaneous Patch; Biological
Lead sponsor: Allerderm; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atrial Fibrillation, Post-Op Complication
Interventions: CardiaMend in Combination with Amiodarone; Combination Product
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Enhancing ADHD Driving Performance With Stimulant Medication

Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)

Smartphone Application to Detect Skin Lesions

Enhancing a High School Based Smoking Cessation Program

Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate

Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias

Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

Study to Evaluate a New Device Designed to Collect Heart Activity and Body Movement Data

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Hypertension in Young Adults Trial

Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals

Skin Sensitization Test (Modified Draize-95 Test)

Validation of Software for Assessment of Atrial Fibrillation From PPG Data Acquired by a Wearable Smartwatch

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

Clinical Evaluation of Metal Panel Allergens: Dose Response Study

Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone